Researchers from Carnegie Mellon University have found a way to make deep brain stimulation (DBS) more precise, resulting in therapeutic effects that outlast what is currently available. The work, led by Aryn Gittis and colleagues in CMU's Gittis Lab, will significantly advance the study of Parkinson's disease. DBS allows researchers and doctors to use thin electrodes implanted in the brain to send electrical signals to the part of the brain that controls movement. It is a proven way to help control unwanted movement in the body, but patients must receive continuous electrical stimulation to get relief from their symptoms. If the stimulator is turned off, the symptoms return immediately.
Gittis, an associate professor of biological sciences in the Mellon College of Science and faculty in the Neuroscience Institute, said that the new research could change that. "By finding a way to intervene that has long-lasting effects, our hope is to greatly reduce stimulation time, therefore minimizing side effects and prolonging battery life of implants."
Gittis set the foundation for this therapeutic approach in 2017, when her lab identified specific classes of neurons within the brain's motor circuitry that could be targeted to provide long-lasting relief of motor symptoms in Parkinson's models. In that work, the lab used optogenetics, a technique that uses light to control genetically modified neurons. Optogenetics, however, cannot currently be used on humans. Since then, she has been trying to find a strategy that is more readily translated to patients suffering from Parkinson's disease. Her team found success in mice with a new DBS protocol that uses short bursts of electrical stimulation. For further information see the IDTechEx report on Bioelectronic Medicine 2019-2029.
"This is a big advance over other existing treatments," Gittis said. "In other DBS protocols, as soon as you turn the stimulation off, the symptoms come back. This seems to provide longer lasting benefits — at least four times longer than conventional DBS."
In the new protocol, the researchers target specific neuronal subpopulations in the globus pallidus, an area of the brain in the basal ganglia, with short bursts of electrical stimulation. Gittis said that researchers have been trying for years to find ways to deliver stimulation in such a cell-type specific manner.
"That concept is not new. We used a 'bottom up' approach to drive cell type specificity. We studied the biology of these cells and identified the inputs that drive them. We found a sweet spot that allowed us to utilize the underlying biology," she said.
Teresa Spix, the first author of the paper, said that while there are many strong theories, scientists do not yet fully understand why DBS works. "We're sort of playing with the black box. We don't yet understand every single piece of what's going on in there, but our short burst approach seems to provide greater symptom relief. The change in pattern lets us differentially affect the cell types," she said.
Spix, who defended her Ph.D. in July, is excited about the direct connection this research has to clinical studies. "A lot of times those of us that work in basic science research labs don't necessarily have a lot of contact with actual patients. This research started with very basic circuitry questions but led to something that could help patients in the near future," Spix said.
Next, neurosurgeons at Pittsburgh's Allegheny Health Network (AHN) will use Gittis' research in a safety and tolerability study in humans. Nestor Tomycz, a neurological surgeon at AHN, said that researchers will soon begin a randomized, double blind crossover study of patients with idiopathic Parkinson's disease. The patients will be followed for 12 months to assess improvements in their Parkinson's disease motor symptoms and frequency of adverse events.
"Aryn Gittis continues to do spectacular research which is elucidating our understanding of basal ganglia pathology in movement disorders. We are excited that her research on burst stimulation shows a potential to improve upon DBS which is already a well-established and effective therapy for Parkinson's disease," Tomycz said.
Donald Whiting, the chief medical officer at AHN and one of the nation's foremost experts in the use of DBS, said the new protocol could open doors for experimental treatments. "Aryn is helping us highlight in the animal model things that are going to change the future of what we do for our patients. She's actually helping evolve the care treatment of Parkinson's patients for decades to come with her research," Whiting said.
Tomycz agreed. "This work is really going to help design the future technology that we're using in the brain and will help us to get better outcomes for these patients."
Source and top image: Carnegie Mellon University